Long-term treatment strategies for atherothrombotic disease: do platelets define the course?
Institute of Cardiology and Center of Excellence on Aging, ‘G. d'Annunzio’ University—Chieti, C/o Ospedale S.S. Annunziata, Via dei Vestini, 66013 Chieti, Italy
* Corresponding author. Tel: +39 0871 41512; fax: +39 0871 402817 E-mail address: m.zimarino{at}unich.it
Atherosclerosis is a slowly progressive disease of the arteries that may undergo a sudden transition to life-threatening conditions following thrombus formation at sites of plaque disruption (atherothrombosis). Platelets play a key role in such late events. This review discusses the evidence supporting the use of oral antiplatelet agents in the long-term prevention of atherothrombotic events.
In ST-elevation acute myocardial infarction and in non-ST elevation acute coronary syndromes, dual antiplatelet therapy with aspirin and clopidogrel has been proved effective in reducing death and myocardial infarction, and prolonged treatment at least up to 1 year is associated with sustained benefit. In some high-risk patients, especially in the setting of urgent percutaneous coronary interventions, adjunctive glycoprotein IIb–IIIa inhibitors confer additional benefit. In chronic coronary artery, cerebrovascular and peripheral arterial disease aspirin reduces the risk of cardiovascular events in both men and women; the adjunctive benefit of clopidogrel is questionable here. In primary prevention, the administration of aspirin is recommended only among patients at high risk.
Key Words: Atherothrombosis • Acute coronary syndromes • Clopidogrel • Prasugrel • AZD16140 • Cangrelor